Definition of the viral targets of protective HIV-1-specific T cell responses
Authors:
- Beatriz MotheBMBeatriz Mothe
- Anuska LlanoALAnuska Llano
- Javier IbarrondoJIJavier Ibarrondo
- Marcus DanielsMDMarcus Daniels
- Cristina MirandaCMCristina Miranda
- Jennifer ZamarreñoJZJennifer Zamarreño
- Vanessa BachVBVanessa Bach
- Rosario ZunigaRZRosario Zuniga
- Susana Pérez-ÁlvarezSPSusana Pérez-Álvarez
- Christoph T BergerCBChristoph T Berger
- Maria C PuertasMPMaria C Puertas
- Javier Martinez-PicadoJMJavier Martinez-Picado
Open Access
- 7 December 2011
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 208
Abstract
Background: The efficacy of the CTL component of a future HIV-1 vaccine will depend on the induction of responses with the most potent antiviral activity and broad HLA class I restriction. However, current HIV vaccine designs are largely based on viral sequence alignments only, not incorporating experimental data on T cell function and specificity. Methods: Here, 950 untreated HIV-1 clade B or -C infected individuals were tested for responses to sets of 410 overlapping peptides (OLP) spanning the entire HIV-1 proteome. For each OLP, a "protective ratio" (PR) was calculated as the ratio of median viral loads (VL) between OLP non-responders and responders. Results: For both clades, there was a negative relationship between the PR and the entropy of the OLP sequence. There was also a significant additive effect of multiple responses to beneficial OLP. Responses to beneficial OLP were of significantly higher functional avidity than responses to non-beneficial OLP. They also had superior in-vitro antiviral activities and, importantly, were at least as predictive of individuals' viral loads than their HLA class I genotypes. Conclusions: The data thus identify immunogen sequence candidates for HIV and provide an approach for T cell immunogen design applicable to other viral infections.Keywords
This publication has 59 references indexed in Scilit:
- Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytesAIDS, 2010
- Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral FitnessJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Viral adaptation to immune selection pressure by HLA class I–restricted CTL responses targeting epitopes in HIV frameshift sequencesJournal of Experimental Medicine, 2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- Adaptation of HIV-1 to human leukocyte antigen class INature, 2009
- Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeysNature, 2008
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnoverJournal of Experimental Medicine, 2007
- Extensive HLA class I allele promiscuity among viral CTL epitopesEuropean Journal of Immunology, 2007
- HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotypeProceedings of the National Academy of Sciences, 2007